Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Remicade Adds Malignancy Warning To Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

New language on lymphoma in the Warnings and Adverse Reactions sections of labeling is substantially similar to that of other TNF-inhibitors – Amgen's Enbrel and Abbott's Humira. J&J is issuing a "Dear Doctor" letter to inform physicians of the changes.

You may also be interested in...



J&J Remicade "Dear Doctor" Letter Warns Of Hepatotoxicity Risk

Remicade label adds warnings on hepatotoxicity and risk of infections relating to pneumonia based on post-marketing reports. FDA approves new indication for the TNF-inhibitor for treatment of ankylosing spondylitis.

J&J Remicade "Dear Doctor" Letter Warns Of Hepatotoxicity Risk

Remicade label adds warnings on hepatotoxicity and risk of infections relating to pneumonia based on post-marketing reports. FDA approves new indication for the TNF-inhibitor for treatment of ankylosing spondylitis.

Humira "Dear Doctor" Letter Emphasizes Class Warning

Abbott's letter reinforces the class warning concerning combination use of Amgen's Kineret and another TNF-inhibitor, the company says. Revised labeling for Humira also includes new warnings regarding hypersensitivity reactions and hematologic events.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel